Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy
- Conditions
- Disorder of Endocrine Pancreas
- Interventions
- Drug: Intramuscular Islet Autograft
- Registration Number
- NCT02872571
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
The liver may not be an optimal site for islet transplantation due to obstacles by an instant blood-mediated inflammatory response, and low revascularization of transplanted islets. Therefore, intramuscular islet transplantation offers an attractive alternative, based on its simplicity, enabling easier access for noninvasive graft imaging and cell explantation.
- Detailed Description
The field of β cell replacement therapies has progressed extensively over the last decades. It is well established that successful intraportal islet transplantation can restore endogenous β cell function to subjects with type 1 diabetes mellitus. In fact, when the graft function is optimal, insulin independence can be consistently prolonged for up to 5 years in 50% of patients. Several factors influence the outcome and performance of the graft upon implantation. For instance, preclinical studies have confirmed the significant differences in utilizing several sites for the implantation of islet grafts, but the most utilized clinical approach is embolization into the liver. However, it has become evidently clear that the liver may not be the optimal environment as a recipient site for pancreatic islets, owing not only to immunologic, but also to anatomic and physiologic factors that may promote a decline in islet function. Moreover, intrahepatic islet infusion is often associated with an immediate blood- mediated inflammatory reaction , thrombosis and hepatic tissue ischemia with elevated blood liver enzymes. In addition, the cross-talk between activated coagulation and inflammatory mediators after implantation, dramatically affects islet cell survival and engraftment, resulting in β cell dysfunction or death, depicting primary nonfunction as a consequence of reduced functional islet mass. This intrahepatic environment appears to potently impair the metabolic functions of transplanted islets. Furthermore, the complications associated with graft recovery within the hepatic site, will further limit its potential applications in exploiting insulin-secreting cells obtained from alternative cell sources. These include xenogenic islets, immortalized β cell lines, embryonic stem cells, or adult progenitor cells, including β cell encapsulation.
Restoration of β cell function is a highly desirable goal for patients with unstable diabetes; therefore, the search for an alternative site that is safer for islet transplantation is imperative.
In man, autotransplantation of minced tissue into striated muscle following blunt dissection has been successfully used in parathyroid surgery for several decades. Initially demonstrated in rodents in the early 1980s, intramuscular islet transplantation (IMIT) has rarely been considered as a clinically feasible implantation site.
This study want to provide direct evidence of the feasibility and function of autologous islets transplanted in the muscle
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 35
age over 18 years indication for pancreatectomy for benign pancreatic disease not genetically determined (chronic pancreatitis, ductal lesions, neuroendocrine or cystic tumors) or pancreatic trauma
Patients with suspected lesion genetically determined or malignant on the basis of preoperative and / or during surgical exploration and / or during pathological examination Refusal to sign the consent form Patient not affiliated with a social security scheme Pregnant or lactating women Persons deprived of liberty, person under guardianship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intramuscular Islet Autograft Intramuscular Islet Autograft Intramuscular Islet Autograft After Extensive Pancreatectomy
- Primary Outcome Measures
Name Time Method the percentage of patients with a functioning graft in the arm 3 months after autograft. 3 months Graft function will be estimated by the difference in insulin response between the two arms after the test stimulus by arginine (Acute Insulin Response or AIRarg) .The graft will be considered functional (success) when the insulin response in the grafted arm will be at least 30% higher compared to the other arm, 3 months after transplantation.
- Secondary Outcome Measures
Name Time Method The percentage of patients with a functioning graft in the arm 6 months, 12 months To demonstrate the function of transplanted islets in the arm in patients receiving autologous islet intramuscularly after undergoing pancreatectomy for benign lesion extent, to prevent post surgical diabetes.
Continuous Glucose Monitoring System at baseline ( before autograft) at 3,6,12 months Continuous recording of blood glucose during 72 hours by Continuous Glucose Monitoring System
Oral Glucose Tolerance Test at baseline ( before autograft) at 3,6,12 months The glucose tolerance test is a medical test in which glucose is given and blood samples taken afterward to determine how quickly it is cleared from the blood.
hemoglobin A1c (HbA1c) blood test at baseline ( before autograft) at 3,6,12 months HbA1c measures blood glucose levels over a period of time.
Trial Locations
- Locations (4)
Institut Paoli Calmettes
🇫🇷Marseille, France
CHU Rouen
🇫🇷Rouen, France
Chu Amiens Picardie
🇫🇷Amiens, France
CHRU, Hôpital Claude Huriez
🇫🇷Lille, France